FDA Approves Rybrevant (amivantamab-vmjw) for Non-small Cell Lung Cancer with EGFR-Exon 20 Mutation
On March 1, 2024, the U.S. Food and Drug Administration (FDA) approved the drug Rybrevant (amivantamab-vmjw) to be given in combination with carboplatin and pemetrexed in the first lining setting for people with metastatic non-small cell lung cancer (NSCLC) with [...]